Kalvista Pharmaceuticals Presented Data On Sebetralstat For Hereditary Angioedema; Sebetralstat Pharmacokinetic And Pharmacodynamic Data Support Globalization Of The KONFIDENT Phase 3 Trial And Use In Short-term Prophylaxis
Portfolio Pulse from Benzinga Newsdesk
Kalvista Pharmaceuticals presented data on Sebetralstat for Hereditary Angioedema, supporting the globalization of the KONFIDENT Phase 3 trial and its use in short-term prophylaxis.
June 12, 2023 | 10:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kalvista Pharmaceuticals' Sebetralstat data supports the globalization of the KONFIDENT Phase 3 trial and its use in short-term prophylaxis for Hereditary Angioedema.
The positive data on Sebetralstat for Hereditary Angioedema supports the globalization of the KONFIDENT Phase 3 trial and its use in short-term prophylaxis. This development is likely to have a positive impact on Kalvista Pharmaceuticals' stock price in the short term as it indicates progress in their product pipeline and potential for future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100